Better Buy: CRISPR Therapeutics vs. Editas Medicine
You can't use traditional means to compare CRISPR Therapeutics (NASDAQ: CRSP) and Editas Medicine (NASDAQ: EDIT) because they are emerging biotech companies with little revenue, and several years between their current efforts and any form of profitability.
Both of these companies are developing medicines that edit genes, using the same CRISPR technology. The system is capable of eliminating mutated DNA that cause a particular disease, such as sickle-cell anemia, some types of blindness, or Alzheimer's.
The potential for CRISPR gene-editing is enormous. A study by Market Insights puts the global gene therapy market at $18.1 billion by 2027, giving it a compound annual growth rate (CAGR) of 25.7%. Figuring out which gene-editing biotech to invest in depends less on their fundamentals and more on which one seems most capable of developing marketable therapies based on the available technology.
Source Fool.com
